Where can I find the primary clinical evidence?

Primary trials are published in peer-reviewed journals (NEJM, JAMA, Lancet) with PubMed PMIDs cited throughout SemaglutideGLPOne.com.

SUSTAIN Trial Results — T2D Cardiovascular Safety

SUSTAIN Trial Results

SUSTAIN-6 (NEJM 2016, PMID 27633186) cardiovascular safety in T2D + high CV risk: 26% MACE reduction. Led to Ozempic's FDA approval.

Clinical referencePubMed-linkedUpdated 2026-05-08

Editorial team

Dr. Sam Saberian · Lead Medical Researcher

Reviewed by Julliana Edwards (Editor) · Last updated 2026-05-08

SUSTAIN-6 (NEJM 2016, PMID 27633186) cardiovascular safety in T2D + high CV risk: 26% MACE reduction. Led to Ozempic's FDA approval.